Aplagon, a Helsinki, Finland-based clinical stage biopharmaceutical company, raised €7M in financing.
The round was led by new investors Fåhraeus Startup and Growth AB (FSG), and European Innovation Council (EIC) Fund, joined by Finnish investors, including Jenny and Antti Wihuri Foundation, Innovestor and Gösta Serlachius Fine Arts Foundation.
The company intends to use the funds to support the initiation of Phase 2a clinical trial of APAC for peripheral arterial occlusive disease/chronic limb threatening ischemia (PAOD/CLTI) in Finland.
Led by CEO Aki Prihti, Aplagon is a clinical stage biopharmaceutical company developing a new therapeutic APAC for treating thrombo-inflammatory diseases. Its first two lead indications are:
- the prevention of AVF maturation failure, to enable lifesaving haemodialysis treatment in end-stage kidney disease patients.
- CLTI, to prevent amputations and other major cardiovascular events in CLTI patients.
APAC is also poised to complete three ongoing clinical trials:
- a Phase I clinical trial for Arteriovenous Fistula (AVF) maturation failure,
- a Phase I intravenous (IV) clinical trial in healthy participants,
- and a PET-imaging clinical trial with 89zirconium-labeled APAC in PAOD patients and healthy participants in 2025.
Johanna Asklin, General Partner at FSG, will join Aplagon as a Board member and Alexander Jöndell, other partner at FSG, as an Observer.
FinSMEs
03/02/2025